These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21882599)

  • 1. [Assay of methylated gene RARbeta2 in circulating DNA of blood from patients with lung cancer as a potential prognostic marker].
    Ponomareva AA; Rykova EIu; Cherdyntseva NV; Skvortsova TE; Dobrodeev AIu; Litviakov NV; Zav'ialov AA; Tuzikov SA; Vlasov VV; Laktionov PP
    Vopr Onkol; 2011; 57(3):302-7. PubMed ID: 21882599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RARβ2 gene methylation level in the circulating DNA from blood of patients with lung cancer.
    Ponomaryova AA; Rykova EY; Cherdyntseva NV; Skvortsova TE; Dobrodeev AY; Zav'yalov AA; Tuzikov SA; Vlassov VV; Laktionov PP
    Eur J Cancer Prev; 2011 Nov; 20(6):453-5. PubMed ID: 21795979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIRA analysis of RARβ2 gene methylation in DNA circulating in the blood in lung cancer.
    Kapitskaya KY; Azhikina TL; Ponomaryova AA; Cherdyntseva NV; Vlasov VV; Laktionov PP; Rykova EY
    Bull Exp Biol Med; 2014 Aug; 157(4):516-9. PubMed ID: 25110096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta.
    Oshita F; Sekiyama A; Suzuki R; Ikehara M; Yamada K; Saito H; Noda K; Miyagi Y
    Oncol Rep; 2003; 10(1):105-8. PubMed ID: 12469153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
    van der Drift MA; Hol BE; Klaassen CH; Prinsen CF; van Aarssen YA; Donders R; van der Stappen JW; Dekhuijzen PN; van der Heijden HF; Thunnissen FB
    Lung Cancer; 2010 May; 68(2):283-7. PubMed ID: 19632736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
    Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
    Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
    Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
    J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum DNA as a tool for cancer patient management.
    Ramirez JL; Taron M; Balaña C; Sarries C; Mendez P; de Aguirre I; Nuñez L; Roig B; Queralt C; Botia M; Rosell R
    Rocz Akad Med Bialymst; 2003; 48():34-41. PubMed ID: 14737938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
    Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer.
    Kim JS; Lee H; Kim H; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Sep; 22(17):3443-50. PubMed ID: 15277540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
    Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
    Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.
    Sozzi G; Conte D; Mariani L; Lo Vullo S; Roz L; Lombardo C; Pierotti MA; Tavecchio L
    Cancer Res; 2001 Jun; 61(12):4675-8. PubMed ID: 11406535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.